Assembly Biosciences Appoints Bridget Hopkins as CEO to Boost European Growth Strategy
- Bridget Hopkins has been appointed CEO of Assembly Biosciences' European operations, effective December 18, 2025.
- Hopkins aims to enhance Assembly's product performance and provide future-ready solutions for the European market.
- Assembly has achieved B Corp certification, highlighting its commitment to social responsibility alongside commercial growth.
Assembly Biosciences Elevates Leadership to Drive European Growth
Assembly Biosciences, a prominent player in the omnichannel media landscape under the Stagwell network, announces the appointment of Bridget Hopkins as the new CEO for its European operations, effective December 18, 2025. This strategic decision reflects the company's commitment to strengthening its presence in Europe amid a rapidly evolving media environment. Based in London, Hopkins has been instrumental in Assembly's regional growth since she joined as Managing Partner in September 2023, and later served as Chief Operating Officer. Her promotion signifies a pivotal moment for Assembly as it aims to enhance its offerings and deliver integrated solutions tailored to the complexities of Europe’s diverse regulatory and cultural landscape.
In her new role, Hopkins seeks to elevate Assembly's product and performance at scale. She emphasizes the importance of providing clients with future-ready solutions that address the unique challenges of the European market. Global CEO Rick Acampora has lauded Hopkins for her operational rigor, commercial insight, and client-centric approach, all of which are essential for accelerating Assembly's growth trajectory within the region. Hopkins has a strong track record in shaping client experiences for notable brands, including Estee Lauder, and her previous experience as Global Client Lead at Wavemaker equips her with the skills necessary to manage complex multi-market engagements effectively.
As Assembly continues to innovate and expand its capabilities, Hopkins’ leadership is expected to reinforce the agency’s status as a premier media partner for brands across Europe and the UK. She articulates a clear commitment to integrating talent, data, and technology to drive scalable growth for clients in an increasingly fragmented media landscape. Assembly’s core values—show up, make change, win well—are integral to its operations and resonate throughout Europe, positioning the agency to deliver greater impact and value for its clients. This leadership transition represents not only a strategic move for Assembly but a broader effort to align with the evolving needs of the marketplace.
In addition to the leadership changes, Assembly has made significant strides in recent years, including expanding into new markets and enhancing its digital commerce capabilities. The agency’s achievement of B Corp certification further underscores its dedication to balancing social and environmental responsibility with commercial success. As Hopkins steps into her new role, the agency is poised to navigate the complexities of the media landscape while solidifying its commitment to client success and sustainable growth.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…